Clinical Trial Detail

NCT ID NCT04303169
Title Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

melanoma

Therapies

Pembrolizumab

MK-7684 + Pembrolizumab

Coxsackievirus A21 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.